United States Patent 3,960,745 Landscape: Scope and Claim Boundaries for Chlorhexidine Skin Cleansing Compositions
United States Patent 3,960,745 is directed to a specific skin cleansing formulation: a defined range of a water-soluble chlorhexidine salt plus a defined polyoxyethylene-polyoxypropylene (PEO-PPO) block copolymer composition, in water. Dependent claims narrow to (i) chlorhexidine gluconate loading, (ii) inclusion of specified amine oxide foaming agents, and (iii) addition of gluconolactone to set pH.
Because this analysis is limited to the claim text provided, it is scoped to claim construction, practical infringement boundaries, and a structured map of likely technical “claim hooks” that drive freedom-to-operate (FTO). It does not identify other patents or litigation without recordable citation data.
What does US Patent 3,960,745 claim for chlorhexidine skin cleansing compositions?
Core claim coverage (Claim 1). Claim 1 defines a “skin cleansing composition” with four essential elements:
- Active antimicrobial component defined by salt identity and solubility
- Chlorhexidine salt in the range of 0.5 to 10.0% w/v, with the salt being soluble to at least 0.5% w/v in water at ambient temperature.
- Salt list is explicit:
- gluconate
- isethionate
- formate
- acetate
- glutamate
- succinamate
- mono-diglycollate
- dimethanesulphonate
- lactate
- diisobutyrate
- glucoheptonate
- Surfactant/solubilizer system defined by block copolymer composition
- 10 to 30% of a polyoxyethylene-polyoxypropylene block copolymer of formula:
- (structural formula provided in the claim as image-equivalent)
- Polymer composition constraints:
- 40 to 70% polyoxyethylene
- molecular weight of the polyoxypropylene content between 2000 and 2500
- These constraints focus the claim on a narrow polymer chemistry “window” rather than generic PEO-PPO broadly.
- Water as the continuous phase
- “and water” is part of the composition.
- “Consisting essentially of”
- “consisting essentially of” limits additional ingredients by allowing only those that do not materially affect the basic and novel characteristics:
- basic cleansing formulation behavior
- the relationship among chlorhexidine salt, specified polymer, and water
- From an infringement standpoint, this clause typically creates a contestable boundary: adding conventional minor excipients is usually permissible, but adding functionally competing surfactants or polymer systems may be argued as materially altering the claimed composition profile.
Claim 1 is essentially a formulation claim with functional solubility gating
The claim’s solubility requirement (“soluble to at least 0.5% w/v in water at ambient temperature”) helps ensure the salt can practically serve as the intended antimicrobial ingredient in a wash product. It also offers a factual gate for design-arounds: formulations using salts not meeting the solubility threshold at ambient conditions risk non-infringement.
How broad is the “chlorhexidine salt” element and what design-arounds exist?
Breadth drivers.
- The active is chlorhexidine, but the claim does not restrict to a single salt. It lists 11 distinct salt types.
- The active level is broad: 0.5 to 10.0% w/v, which covers many topical antimicrobial wash concentrations.
Key limiting drivers.
- The solubility threshold: ≥0.5% w/v in water at ambient temperature.
- The salt must be “selected from the group consisting of” the enumerated salts. Substituting another chlorhexidine salt outside that list is a direct non-infringement strategy if the substituted salt is not in the enumerated group.
- If a listed salt is used but fails the solubility requirement at ambient temperature in the product’s actual conditions (buffering, temperature, ionic strength), infringement can be contested.
Salt-specific claim implications
- Chlorhexidine gluconate is both listed in Claim 1 and singled out in Claim 2 (0.5 to 5.0%).
- The explicit list means a competitor cannot “pick an unlisted salt” and still read on Claim 1, even if it is chlorhexidine and is soluble.
What does the PEO-PPO block copolymer limitation mean in claim terms?
Claim 1 restricts the copolymer by:
- presence at 10–30% in the composition
- polymer chemistry:
- PEO fraction 40–70%
- PPO molecular weight 2000–2500 (for the polyoxypropylene segment)
What this does operationally
A generic “poloxamer” type material can fall into this family, but not all will meet the exact percentage and PPO molecular weight constraints. From an FTO standpoint, the decisive question is whether the chosen commercial polymer’s specification matches:
- polyoxyethylene weight fraction in the stated 40–70% range
- PPO segment molecular weight in the 2000–2500 range
If a competitor uses a different PEO-PPO with PPO segment outside 2000–2500, or PEO fraction outside 40–70%, it can position non-infringement on the polymer element.
What is the practical scope of “skin cleansing composition” and “consisting essentially of”?
The claim does not define “skin cleansing” by test method, consumer use, or regulated category. It is a formulation context term.
“Consisting essentially of” matters for ingredient selection:
- The claim allows additional ingredients so long as they do not materially affect the novel characteristics.
- Dependent Claim 3 and Claim 4 demonstrate that foaming agents and pH adjusters are contemplated, which supports that minor excipients are likely within the allowed envelope.
- Conversely, adding a different polymer system in significant amount (or swapping out the defined PEO-PPO component) likely changes the surfactant architecture and can be argued to materially alter the formulation’s defining characteristics.
How do dependent claims narrow the formulation?
Claim 2: Chlorhexidine gluconate dosage window
- Requires the formulation of Claim 1 contain 0.5 to 5.0% chlorhexidine gluconate.
This is a narrower dosage constraint relative to Claim 1’s 0.5 to 10.0% w/v chlorhexidine salt. The claim is not framed as a subset by identity only; it is framed as a subset by both identity (gluconate) and concentration.
Infringement consequence.
- A product using chlorhexidine gluconate at >5.0% w/v likely avoids Claim 2 while still potentially infringing Claim 1 if the polymer and other elements are met.
Claim 3: Specified amine oxide foaming agents
- Adds an amine oxide foaming agent selected from:
- cetyldimethylamine oxide
- lauryldimethylamine oxide
- cetylmethylmyristylamine oxide
- dimethylmyristylamine oxide
Infringement consequence.
- If a competitor uses a different foaming agent (e.g., betaines, sulfates, non-listed amine oxides) it may still fall within Claim 1 (if “consisting essentially of” is satisfied) but avoid Claim 3.
Claim 4: Gluconolactone to set pH
- Adds gluconolactone to provide pH between 5 and 7.
Infringement consequence.
- If pH is set via other acid/base systems without gluconolactone, it may avoid Claim 4 while still infringing independent Claim 1 if pH constraints are not otherwise limiting independent coverage (Claim 1 does not state a pH range).
What is the claim-by-claim “infringement matrix” for product formulation?
| Product element |
Must match for Claim 1 |
Additional must match for Claim 2 |
Additional must match for Claim 3 |
Additional must match for Claim 4 |
| Chlorhexidine salt |
0.5–10.0% w/v; listed salt; ≥0.5% w/v solubility in water at ambient temp |
must be chlorhexidine gluconate at 0.5–5.0% w/v |
no extra chlorhexidine restriction |
no extra chlorhexidine restriction |
| PEO-PPO block copolymer |
10–30%; PEO 40–70%; PPO molecular weight 2000–2500 |
none |
none |
none |
| Water |
present |
present |
present |
present |
| “consisting essentially of” limitation |
additional ingredients must not materially alter basic novel characteristics |
same |
same; foamer must be one of listed amine oxides |
same; pH created by gluconolactone to pH 5–7 |
How strong is the patent estate likely to be based on the claim structure?
Within the provided claim set, strength is driven by two features:
- Multiple, conjunctive technical limitations
- The claim is not just “chlorhexidine + polymer.” It requires the specific salt list, concentration range, solubility threshold, and a narrowly parameterized PEO-PPO copolymer window.
- Dependent claims add concrete formulation constraints
- Concentration narrowing (Claim 2), specific foaming agents (Claim 3), and a specific pH-setter (Claim 4) offer incremental enforcement paths against variants.
Weaknesses typical for this style (claim text indicates).
- The phrase “skin cleansing composition consisting essentially of” creates a litigation-sensitive boundary about what constitutes materially affecting basic and novel characteristics.
- The polymer constraints invite non-infringement if a competitor uses a slightly different PEO/PPO with PPO MW outside 2000–2500 or PEO fraction outside 40–70%.
How do “formulation variants” affect claim coverage?
Variant 1: Same actives and polymer, but different salt from the list
- Using a listed salt identity can still meet the “selected from” requirement.
- If the salt is listed but does not reach ≥0.5% w/v solubility at ambient temperature in the actual product matrix, Claim 1 can be avoided.
Variant 2: Same salt and copolymer, but copolymer percentage outside 10–30%
- If copolymer is <10% or >30%, it avoids Claim 1.
Variant 3: Same copolymer but polymer chemistry slightly outside constraints
- If PEO fraction or PPO segment molecular weight is outside bounds, it avoids Claim 1.
Variant 4: Chlorhexidine gluconate at >5% w/v
- Likely avoids Claim 2 while still potentially infringing Claim 1 if other elements match.
Variant 5: Same composition, different foaming agent
- Avoids Claim 3 but potentially still infringes Claim 1.
Variant 6: Same composition, pH controlled without gluconolactone
- Avoids Claim 4; independent Claim 1 still does not expressly require pH 5–7.
What patent landscape is created by dependent claim differentiation (Claim 2–4)?
Even without other patents cited, the dependent claim structure shows how competitors would split design-around strategies:
- Dosage design-around: push chlorhexidine gluconate concentration above 5.0% w/v while staying within chlorhexidine salt range for Claim 1.
- Foamer design-around: replace listed amine oxides with other foaming systems.
- pH design-around: replace gluconolactone with different pH-adjusting agents and operate outside pH 5–7 where feasible.
This is the practical map for freedom-to-operate planning around this particular claim family.
How does this claim language compare with typical US formulation claiming patterns?
Compared with broader antimicrobial formulations, this claim is:
- more specific on salt identity (enumerated group)
- more specific on solubility threshold
- more specific on polymer composition and molecular weight window
- more specific through dependent narrowing (gluconate amount, specific foaming agents, gluconolactone pH range)
Compared with broader process claims (manufacturing steps), it is purely composition-based. That means non-infringement can be achieved at the formulation level without altering manufacturing process.
Key Takeaways
- Claim 1 covers skin cleansing compositions with 0.5–10% w/v of a listed water-soluble chlorhexidine salt meeting ≥0.5% w/v solubility at ambient temperature, plus 10–30% of a PEO-PPO block copolymer with PEO 40–70% and PPO MW 2000–2500, in water, under “consisting essentially of.”
- Claim 2 adds a narrower chlorhexidine gluconate concentration window (0.5–5% w/v).
- Claim 3 narrows further to specific amine oxide foaming agents.
- Claim 4 narrows further to use of gluconolactone to achieve pH 5–7.
- The tight polymer and salt constraints make formulation substitutions (salt choice outside the list, polymer spec outside windows, different foamer, different pH-setter) the primary levers for avoiding infringement.
FAQs
-
Can a chlorhexidine salt formulation avoid Claim 1 by using a different chlorhexidine salt not listed in the claim?
Yes, using a salt outside the enumerated “selected from” group avoids the Claim 1 active component limitation.
-
If chlorhexidine gluconate is used at 6% w/v with the same polymer and other ingredients, which claims are implicated?
Claim 2’s 0.5–5.0% gluconate window would be avoided, but Claim 1 can still be implicated if all Claim 1 elements are met.
-
Does Claim 3 require that the foaming agent be the only surfactant in the product?
The claim requires inclusion of an amine oxide foaming agent selected from the listed group, while “consisting essentially of” governs whether other ingredients materially alter the composition’s basic characteristics.
-
Is pH 5–7 a requirement for infringement of Claim 1?
No. The pH requirement is only explicitly tied to Claim 4 via gluconolactone.
-
What polymer changes most likely defeat Claim 1?
Using a PEO-PPO block copolymer where the PEO fraction is outside 40–70% or the PPO segment molecular weight is outside 2000–2500, or using polymer amounts outside 10–30%.
References
- United States Patent 3,960,745 (claims as provided in prompt).
